Curcumin promotes cell cycle arrest and apoptosis of acute myeloid leukemia cells by inactivating AKT

Zhou,Hao; Ning,Yichong; Zeng,Guirong; Zhou,Chang; Ding,Xiaofeng

doi:10.3892/or.2021.7962

Curcumin promotes cell cycle arrest and apoptosis of acute myeloid leukemia cells by inactivating AKT

Authors:
- Hao Zhou
- Yichong Ning
- Guirong Zeng
- Chang Zhou
- Xiaofeng Ding
View Affiliations

Affiliations: State Key Laboratory of Developmental Biology of Freshwater Fish, College of Life Sciences, Hunan Normal University, Changsha, Hunan 410081, P.R. China, Department of Clinical Laboratory, Chongzuo People's Hospital, Chongzuo, Guangxi 532200, P.R. China, Hunan Key Laboratory of Pharmacodynamics and Safety Evaluation of New Drugs and Hunan Provincial Research Center for Safety Evaluation of Drugs, Changsha, Hunan 410331, P.R. China, The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, Hunan 410081, P.R. China
Published online on: February 2, 2021 https://doi.org/10.3892/or.2021.7962
Article Number: 11
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Curcumin, a phytochemical from rhizomes of the plant Curcuma longa, has been reported to exert potential anticancer properties in various cancer types, including acute myeloid leukemia (AML). However, the underlying mechanism remains poorly understood. The present study demonstrated that curcumin had a stronger cytotoxic activity against AML cells compared with three other types of phytochemicals (epigallocatechin gallate, genistein and resveratrol). Protein phosphorylation profiling using an antibody array identified that curcumin treatment increased the phosphorylation levels of 14 proteins and decreased those of four proteins. A protein‑protein interaction network was constructed using the STRING database, in which AKT was identified as a hub protein with the highest connectivity (PRAS40, 4E‑BP1, P70S6K, RAF‑1 and p27). Western blotting results indicated that curcumin dose‑dependently suppressed the phosphorylation of AKT, PRAS40, 4E‑BP1, P70S6K, RAF‑1 and p27 in AML cell lines (ML‑2 and OCI‑AML5). It was also demonstrated that curcumin regulated the cell cycle‑ and apoptosis‑related proteins (cyclin D1, p21, Bcl2, cleaved‑caspase‑3 and cleaved‑PARP), leading to cell cycle arrest and apoptosis in both ML‑2 and OCI‑AML5 cells. These effects of curcumin were enhanced by the AKT inhibitor afuresertib but were suppressed by the AKT activator SC‑79, indicating that curcumin functions via AKT. In the AML xenograft mouse model, curcumin and afuresertib synergistically suppressed the engraftment, proliferation and survival of AML cells. Collectively, the present study demonstrated that curcumin exerted anti‑AML roles by inactivating AKT and these findings may aid in the treatment of AML.

View Figures

View References

1	Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015. View Article : Google Scholar : PubMed/NCBI
2	Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, et al: Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 17:721–749. 2019. View Article : Google Scholar
3	Oran B and Weisdorf DJ: Survival for older patients with acute myeloid leukemia: A population-based study. Haematologica. 97:1916–1924. 2012. View Article : Google Scholar : PubMed/NCBI
4	Sami SA, Darwish NHE, Barile ANM and Mousa SA: Current and future molecular targets for acute myeloid leukemia therapy. Curr Treat Options Oncol. 21:32020. View Article : Google Scholar : PubMed/NCBI
5	Wang XJ, Chen JY, Fu LQ and Yan MJ: Recent advances in natural therapeutic approaches for the treatment of cancer. J Chemother. 32:53–65. 2020. View Article : Google Scholar : PubMed/NCBI
6	Kian MM, Salemi M, Bahadoran M, Haghi A, Dashti N, Mohammadi S, Rostami S, Chahardouli B, Babakhani D and Nikbakht M: Curcumin combined with thalidomide reduces expression of STAT3 and Bcl-xL, leading to apoptosis in acute myeloid leukemia cell lines. Drug Des Devel Ther. 14:185–194. 2020. View Article : Google Scholar : PubMed/NCBI
7	Liang K, Bae KH, Nambu A, Dutta B, Chung JE, Osato M and Kurisawa M: A two-pronged anti-leukemic agent based on a hyaluronic acid-green tea catechin conjugate for inducing targeted cell death and terminal differentiation. Biomater Sci. 8:497–505. 2019. View Article : Google Scholar : PubMed/NCBI
8	de Blas E, Estañ MC, Del Carmen Gomez de Frutos M, Ramos J, Del Carmen Boyano-Adánez M and Aller P: Selected polyphenols potentiate the apoptotic efficacy of glycolytic inhibitors in human acute myeloid leukemia cell lines. Regulation by protein kinase activities. Cancer Cell Int. 16:702016. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Guo Y, Feng Z, Bergan R, Li B, Qin Y, Zhao L, Zhang Z and Shi M: Involvement of the PI3K/Akt/Nrf2 signaling pathway in resveratrol-mediated reversal of drug resistance in HL-60/ADR cells. Nutr Cancer. 71:1007–1018. 2019. View Article : Google Scholar : PubMed/NCBI
10	Giordano A and Tommonaro G: Curcumin and cancer. Nutrients. 11:23762019. View Article : Google Scholar
11	Liczbinski P, Michałowicz J and Bukowska B: Molecular mechanism of curcumin action in signaling pathways: Review of the latest research. Phytother Res. 34:1992–2005. 2020. View Article : Google Scholar : PubMed/NCBI
12	Borges GA, Elias ST, Amorim B, de Lima CL, Coletta RD, Castilho RM, Squarize CH and Guerra EN: Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells. Phytother Res. 34:3311–3324. 2020. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Sun W, Han N, Zou Y and Yin D: Curcumin inhibits proliferation, migration, invasion and promotes apoptosis of retinoblastoma cell lines through modulation of miR-99a and JAK/STAT pathway. BMC Cancer. 18:12302018. View Article : Google Scholar : PubMed/NCBI
14	Hosseini A, Rasmi Y, Rahbarghazi R, Aramwit P, Daeihassani B and Saboory E: Curcumin modulates the angiogenic potential of human endothelial cells via FAK/P-38 MAPK signaling pathway. Gene. 688:7–12. 2019. View Article : Google Scholar : PubMed/NCBI
15	Zhou J, Duan H, Xie Y, Ning Y, Zhang X, Hui N, Wang C, Zhang J and Zhou J: MiR-193a-5p targets the coding region of AP-2alpha mRNA and induces cisplatin resistance in bladder cancers. J Cancer. 7:1740–1746. 2016. View Article : Google Scholar : PubMed/NCBI
16	Kouhpeikar H, Butler AE, Bamian F, Barreto GE, Majeed M and Sahebkar A: Curcumin as a therapeutic agent in leukemia. J Cell Physiol. 234:12404–12414. 2019. View Article : Google Scholar : PubMed/NCBI
17	Zhou C, Zhao XM, Li XF, Wang C, Zhang XT, Liu XZ, Ding XF, Xiang SL and Zhang J: Curcumin inhibits AP-2γ-induced apoptosis in the human malignant testicular germ cells in vitro. Acta Pharmacol Sin. 34:1192–1200. 2013. View Article : Google Scholar : PubMed/NCBI
18	Yang L, Qiu J, Xiao Y, Hu X, Liu Q, Chen L, Huang W, Li X, Li L, Zhang J, et al: AP-2βinhibits hepatocellular carcinoma invasion and metastasis through Slug and Snail to suppress epithelial-mesenchymal transition. Theranostics. 8:3707–3721. 2018. View Article : Google Scholar : PubMed/NCBI
19	Carlos-Reyes A, Lopez-Gonzalez JS, Meneses-Flores M, Gallardo-Rincón D, Ruíz-García E, Marchat LA, Astudillo-de la Vega H, de la Cruz ON and López-Camarillo C: Dietary compounds as epigenetic modulating agents in cancer. Front Genet. 10:792019. View Article : Google Scholar : PubMed/NCBI
20	He X and Zhang J: Why do hubs tend to be essential in protein networks? PLoS Genet. 2:e882006. View Article : Google Scholar : PubMed/NCBI
21	Masamha CP and Benbrook DM: Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 69:6565–6572. 2009. View Article : Google Scholar : PubMed/NCBI
22	Georgakilas AG, Martin OA and Bonner WM: p21: A two-faced genome guardian. Trends Mol Med. 23:310–319. 2017. View Article : Google Scholar : PubMed/NCBI
23	Prijic S, Ugrina I, Labar B, Nemet D, Batinić J, Zadro R, Ries S, Gjadrov-Kuvedžić K, Davidović S and Batinić D: Prognostic significance of constitutive phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia. Leuk Lymphoma. 56:2281–2288. 2015. View Article : Google Scholar : PubMed/NCBI
24	Qin Z, Li Y, Li Y and Liu G: Tumor necrosis factor alpha stimulates proliferation of dental pulp stem cells via akt/glycogen synthase kinase-3β/cyclin D1 signaling pathway. J Endod. 41:1066–1072. 2015. View Article : Google Scholar : PubMed/NCBI
25	Hu Z, Long T, Ma Y, Zhu J, Gao L, Zhong Y, Wang X, Wang X and Li Z: Downregulation of GLYR1 contributes to microsatellite instability colorectal cancer by targeting p21 via the p38MAPK and PI3K/AKT pathways. J Exp Clin Cancer Res. 39:762020. View Article : Google Scholar : PubMed/NCBI
26	Wan YJ, Yang Y, Leng QL, Lan B, Jia HY, Liu YH, Zhang CZ and Cao Y: Vav1 increases bcl-2 expression by selective activation of rac2-akt in leukemia T cells. Cell Signal. 26:2202–2209. 2014. View Article : Google Scholar : PubMed/NCBI
27	Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou E, et al: Phase IB dose escalation and expansion study of AKT inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer. Clin Cancer Res. 25:1472–1478. 2019. View Article : Google Scholar : PubMed/NCBI
28	Yamaji M, Ota A, Wahiduzzaman M, Karnan S, Hyodo T, Konishi H, Tsuzuki S, Hosokawa Y and Haniuda M: Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 6:2646–2659. 2017. View Article : Google Scholar : PubMed/NCBI
29	Chen CI, Paul H, Le LW, Wei EN, Snitzler S, Wang T, Levina O, Kakar S, Lau A, Queau M, et al: A phase 2 study of ofatumumab (Arzerra^®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 60:92–100. 2019. View Article : Google Scholar : PubMed/NCBI